Abstract
Lecanemab the humanized IgG1 mAB, is administered intravenously, and binds to Aβ species. It is the only drug among all the currently available treatments that shows a 37\% decline of the abnormal Aβ protein plaques and slowes the loss of the brain function. This drug works in patients in the starting stages of Alzheimer's and dementia. On January 6, 2023, Leqembi got its first FDA approval after its second‑phase clinical trial run by EISAI and Biogen. There are more future studies that are going on and are expected to determine the slowing of not only the Aβ proteins but also to reduce the tau protein mutations in its preclinical stage, which would allow us for the easier administration and accessibility to a better understanding of dementia.
Recommended Citation
Srivastav, Saumya
(2025)
"Leqembi: A Breakthrough in the Treatment of Alzheimer's Disease: A Mini Report,"
Indian Journal of Health Sciences and Biomedical Research KLEU: Vol. 18:
Iss.
1, Article 4.
Available at:
https://kleijhsbr.researchcommons.org/journal/vol18/iss1/4